ClearB Therapeutics

ClearB Therapeutics is a clinical-stage biotechnology company developing immune-based therapies designed to achieve a functional cure for chronic hepatitis B (CHB), a disease affecting over 250 million people worldwide. Co-founded in 2017 by Morningside Ventures in collaboration with Professor Stephen Locarnini and the Victorian Infectious Diseases Reference Laboratory (VIDRL) in Melbourne, Australia, ClearB's science is grounded in proprietary insights into how hepatitis B surface antigens can be targeted to redirect the patient's immune system. The company's lead program, CLB-3000, is a therapeutic vaccine in Phase 1b clinical trials. ClearB also has CLB-4000, a second candidate for which a sentinel safety cohort has been evaluated in a first-in-human study. The company is funded by Morningside Ventures and is headquartered in Concord, Massachusetts, with scientific roots in Australia.